Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients
Authors:
Open Access
- 13 February 2013
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 24 (6) , 1691-1697
Abstract
BRAF inhibitors are being developed for the treatment of metastatic melanoma harboring a V600E mutation. The use of vemurafenib significantly increases progression-free survival (PFS) and overall survival (OS) in this population of patients, but is associated with numerous adverse skin reactions. We carried out a systematic dermatologic study of 42 patients treated with vemurafenib. We collected detailed dermatologic symptoms, photos and biopsy specimens of the skin lesions which enabled us to classify the side-effects. The management and evolution of the skin symptoms are also reported. All patients presented with at least one adverse skin reaction. The most common cutaneous side-effects consisted in verrucous papillomas (79%) and hand–foot skin reaction (60%). Other common cutaneous toxic effects were a diffuse hyperkeratotic perifollicular rash (55%), photosensitivity (52%) and alopecia (45%). Epidermoid cysts (33%) and eruptive nevi (10%) were also observed. Keratoacanthomas (KA) and squamous cell carcinoma (SCC) occurred in 14% and 26% of the patients, respectively. These cutaneous side-effects are cause of concern due to their intrinsic potential for malignancy or because of their impact on patients' quality of life. Management of this skin toxicity relies on symptomatic measures and sun photoprotection.Keywords
This publication has 20 references indexed in Scilit:
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF InhibitorsNew England Journal of Medicine, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Overcoming metastatic melanoma with BRAF inhibitorsArchives of Pharmacal Research, 2011
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growthNature, 2010
- Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving SorafenibJournal of Clinical Oncology, 2009
- p16INK4a immunostaining in cytological and histological specimens from the uterine cervix: A systematic review and meta-analysisCancer Treatment Reviews, 2009
- Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase InhibitorArchives of Dermatology, 2008
- Sorafenib-Induced Eruptive Melanocytic LesionsArchives of Dermatology, 2008
- Autosomal-Dominant Calcium ATPase DisordersJournal of Investigative Dermatology, 2006
- Mutations of the BRAF gene in human cancerNature, 2002